Journal
NEUROBIOLOGY OF AGING
Volume 30, Issue 8, Pages 1217-1226Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2007.11.005
Keywords
Alzheimer's disease; Microglia; PET; PK11195; Peripheral benzodiazepine receptor; Astrocyte
Categories
Funding
- National Institutes of Health [RO1 MH64921, K24 MH01717, R21 AG025829, RO1 AG020226]
- Alzheimer Disease Research Center (RLH) [P50 AG05133-21]
Ask authors/readers for more resources
Activated microglia may promote neurodegeneration in Alzheimer's disease (AD) and may also help in amyloid clearance in immunization therapies. In vivo imaging of activated microglia using positron emission tomography (PET) could assist in defining the role of activated microglia during AD progression and therapeutics. We hypothesized that PK11195, a ligand that binds activated microglia, could label these cells in postmortem AD tissues and in vivo in an animal model of AD using PET. [H-3](R)-PK11195 binding was significantly higher in AD frontal cortex compared to controls and correlated mainly with the abundance of immunohistochemically labeled activated microglia. With age, the brains of APP/PS1 transgenic mice showed progressive increase in [H-3](R)-PK11195 binding and [C-11](R)-PK11195 retention in vivo assessed using microPET, which correlated with the histopathological abundance of activated microglia. These results suggest that PK11195 binding in AD postmortem tissue and transgenic mice in vivo correlates with the extent of microglial activation and may help define the role of activated microglia in the pathogenesis and treatment of AD. (C) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available